Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®). HTA ID: 23073

Assessment Status Rapid Review Complete
HTA ID 23073
Drug Tremelimumab
Brand Imjudo®
Indication Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma.
Assessment Process
Rapid review commissioned 06/12/2023
Rapid review completed 11/01/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tremelimumab in combination with durvalumab compared with the current standard of care.